Combination treatment for recurrent head and neck cancer after pembrolizumab failure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a combination treatment involving carboplatin, paclitaxel, and cetuximab in adult patients with recurrent or metastatic head and neck squamous cell carcinoma who have not responded to prior treatment with pembrolizumab, with or without chemotherapy. The main goal is to assess the objective response rate of this treatment regimen, while secondary objectives include monitoring disease progression, treatment tolerance, and quality of life over a 12-month participation period. Patients will be recruited from medical oncology departments in France.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age greater than or equal to 18 years at inclusion
2. Cytological or histological confirmation of the diagnosis of invasive squamous cell carcinoma of the head and neck
3. One of the following locations: oral cavity, oropharynx (known p16 status), larynx or hypopharynx
4. Cancers of unknown primary (CUP) of the head and neck are accepted
5. Metastatic (stage IVc) or recurrent disease in patients ineligible for curative surgical treatment or radiotherapy
6. Indication of a 2nd line after pembrolizumab +/- chemotherapy
7. Chemotherapy-free interval ≥ 3 months
8. ECOG Performance Index (Performance Index) of 0, 1 or 2
9. Patient with a life expectancy of at least 12 weeks
10. Documented progression of a measurable tumor target according to RECIST 1.1
11. Correct biology
12. Patient (male or female of childbearing potential) using a highly effective contraceptive method
13. Willingness and ability to comply with the visit schedule, treatment regimens, examinations and other procedures planned in the study
14. Patient enrolled in a health insurance plan or beneficiary of such a plan
15. Signed informed consent obtained before inclusion (after giving clear, fair and appropriate information)

Exclusion Criteria:

1. Other histology
2. Nasal, paranasal and nasopharyngeal cavities
3. Symptomatic or active brain parenchymal metastases or leptomeningeal tumors
4. Grade ≥2 neuropathy
5. Patients may have previously received radiotherapy. A minimum period of 2 weeks is necessary between palliative or analgesic radiotherapy and the start of treatment
6. Clinically significant heart disease or congestive heart failure NYHA (New York Heart Association) class 2 or greater. Patients must not have had unstable angina (symptoms of angina at rest) or new angina in the last 3 months or myocardial infarction in the last 6 months.
7. History of other primary malignancies, except curatively treated malignancies with no evidence of recurrence, within 3 years before the first dose of treatment and a low potential risk of recurrence or non-recurrent skin cancer. melanoma or lentigo maligna properly treated without evidence of disease or carcinoma in situ adequately treated without evidence of disease. A history of T1 grade bladder cancer or T1 grade kidney cancer is accepted. Cervical carcinoma in situ or breast cancer in situ are accepted. Patients with papillary thyroid carcinoma, basal cell skin carcinoma are accepted. A history of prostate cancer is allowed if it is less than or equal to stage T2N0M0 and a Gleason score of 6.
8. Known hypersensitivity to the active substance or excipient of the treatments under study
9. Any uncontrolled intercurrent pathology
10. Any psychiatric illness/social situation that may limit compliance with study procedures or prevent the patient from giving written informed consent
11. Any chemotherapy or radiotherapy performed within 4 weeks of the first dose of study drug, except palliative radiotherapy to a non-target lesion
12. Major surgery within 4 weeks before the first administration of treatment. Local palliative surgery for isolated lesions is tolerated
13. Phenytoin prescribed for prophylaxis
14. Administration of a live attenuated vaccine within 30 days before the first administration of study treatment, as well as during the duration of study treatment and up to 6 months after the last dose of treatment
15. Participation in another clinical trial of an investigational treatment during the 4 weeks preceding the first administration of the study treatment
16. Pregnant or breastfeeding women
17. Women of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment.
18. Patients presenting hemorrhagic tumor
19. History of allergy to red meat or tick bites or positive results of tests for IgE antibodies against cetuximab (α-1-3-galactose)
20. Patient presenting interstitial lung disease
21. History of organ transplant
22. Concomitant treatment with Hypericum

Where it's running

• Centre hospitalier Régional de Metz-Thionville
  Ars-Laquenexy, France Recruiting
• CHU de Besançon
  Besançon, France Recruiting
• Centre Hospitalier de Colmar
  Colmar, France Recruiting
• Centre Paul Strauss
  Strasbourg, France Recruiting
• Institut de cancérologie de Lorraine
  Vandœuvre-lès-Nancy, France Recruiting

Study contacts

• Principal investigator: Carole PFLUMIO, MD — Centre Paul Strauss
• Study coordinator: Manon VOEGELIN
• Email: promotion-rc@icans.eu
• Phone: 3687339523

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer

  In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07882888

• Cetuximab with PD-1 therapy plus chemotherapy vs PD-1 therapy with chemotherapy for recurrent/metastatic head and neck cancer

  This trial tests whether adding cetuximab to a PD-1 inhibitor plus chemotherapy helps people with recurrent or metastatic head and neck squamous cell cancer who aren’t candidates for curative treatment.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality and 1 other locations · NCT07509099

• Pembrolizumab with ultrasound-induced microbubble cavitation for recurrent or metastatic head and neck cancer

  We will try giving pembrolizumab together with ultrasound-triggered microbubbles to people with HPV-negative recurrent or metastatic head and neck cancer to help the drug reach tumors and improve response.

  Recruiting Phase 1 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07501650

• Zanzalintinib with pembrolizumab and cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial tests whether adding the oral drug zanzalintinib to pembrolizumab and cetuximab is safe and finds the best dose for adults with recurrent or metastatic head and neck squamous cell cancer.

  Recruiting Phase 1 University of Chicago · Chicago, Illinois · NCT06912087

• Cetuximab with or without weekly paclitaxel after progression on pembrolizumab plus platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial tests whether adding weekly paclitaxel to cetuximab helps people with recurrent or metastatic head and neck squamous cell carcinoma whose cancer progressed after first‑line pembrolizumab plus platinum/5‑FU.

  Recruiting at 16 sites Phase 2 Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Santiago de Compostela, A Coruña and 16 other locations · NCT06856213

• Combining cetuximab with pembrolizumab for advanced head and neck cancer

  This study is testing if adding cetuximab to pembrolizumab can help people with advanced head and neck cancer live longer and feel better compared to just using pembrolizumab alone.

  Recruiting at 192 sites Phase 3 National Cancer Institute (NCI) · Little Rock, Arkansas and 201 other locations · NCT06589804

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.